10-K: Molina Healthcare's 2025 Profit Dip Amidst Growth

Molina Healthcare reports a significant decline in net income for 2025 despite robust revenue growth, driven by rising medical costs and strategic shifts in its government-sponsored healthcare segments.

Summary

• Net income decreased to $472 million in 2025 from $1,179 million in 2024, with diluted EPS falling to $8.92 from $20.42.
• Total revenue increased 12% to $45.4 billion in 2025, and premium revenue grew 11% to $43.1 billion.
• The consolidated Medical Care Ratio (MCR) rose to 91.7% in 2025 from 89.1% in 2024, reflecting a challenging medical cost trend and acuity shifts.
• Membership slightly decreased to 5.491 million as of December 31, 2025, from 5.535 million in 2024, primarily due to Medicaid redeterminations.
• The General and Administrative (G&A) expense ratio improved to 6.6% in 2025 from 6.7% in 2024.
• Molina closed the ConnectiCare acquisition on February 1, 2025, for $350 million, adding approximately 140,000 members.
• The company plans to exit its Medicare Advantage-Part D (MAPD) product for 2027, which represented 117,000 members and $1.566 billion in Medicare premium revenue in 2025.
• New Medicaid contract wins in 2025, including Florida and Wisconsin, represent nearly $9 billion of incremental annual premium revenue.
• A putative securities class action and a shareholder derivative suit were filed against the company and its officers/directors in late 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging year for Molina Healthcare, marked by a significant decline in profitability and increased medical costs, despite strong revenue growth and strategic contract wins. The negative financial performance and the temporary reduction in credit covenant thresholds outweigh the positive growth initiatives and operational efficiencies.

Positives

• Total revenue increased 12% to $45.4 billion in 2025, demonstrating strong top-line growth.
• Premium revenue increased 11% to $43.1 billion, driven by acquisitions, Medicaid rate increases, and Marketplace membership growth.
• The General and Administrative (G&A) ratio decreased to 6.6% from 6.7%, indicating improved operating discipline and leverage.
• Molina achieved a 90% re-procurement win rate for Medicaid requests for proposal (RFP) and an 80% new contract win rate, securing approximately $9 billion in incremental annual Medicaid premium revenue in 2025.
• The ConnectiCare acquisition, closed February 1, 2025, added approximately 140,000 members and contributed to growth.
• The company maintains a long-term premium revenue growth target of 11% to 13% and is on pace to surpass $50 billion in premium revenue by 2027.
• Molina returned $1 billion to shareholders in 2025 through common stock repurchase programs.
• Regulated health plans paid $985 million in dividends to the parent company in 2025, reflecting cash in excess of capital needs.
• The company refinanced its revolving credit facility with a new $1.25 billion facility, extending the term to November 20, 2030, and maintains a weighted average cost of fixed debt at 5.0%.
• 18 Medicaid and 14 Marketplace health plans are accredited by the NCQA, with 18 Medicaid and 13 Marketplace plans earning Health Equity Accreditation, demonstrating commitment to quality.
• Medicare Star Ratings for 2026 improved, with two additional plans reaching 3.5 Stars and one reaching 4.5 Stars, strengthening future rebates and Quality Bonus Payments.
• Management concluded that the company maintained effective internal control over financial reporting as of December 31, 2025.

Negatives

• Net income significantly decreased to $472 million in 2025 from $1,179 million in 2024, a 60% decline.
• Net income per diluted share dropped to $8.92 in 2025 from $20.42 in 2024.
• The consolidated Medical Care Ratio (MCR) increased to 91.7% in 2025 from 89.1% in 2024, exceeding the company's long-term target range due to higher utilization and acuity shifts.
• Pre-tax margin declined substantially to 1.3% in 2025 from 3.9% in 2024.
• Medicaid membership decreased due to eligibility redeterminations, and the remaining population had higher acuity, leading to elevated cost trends.
• The One Big Beautiful Bill Act (OBBBA) is expected to reduce Medicaid Expansion membership by 15% to 20% by 2029 and may reduce state revenues from provider taxes.
• The expiration of subsidies in Marketplace in 2025 is expected to lead to a reduction in membership and an adverse acuity shift in the overall market risk pool.
• Investment income decreased to $420 million in 2025 from $452 million in 2024 due to a decline in prevailing interest rates and investment yields.
• Interest expense increased to $192 million in 2025 from $118 million in 2024 due to new debt issuances.
• Net cash used in operating activities was $535 million in 2025, a significant decrease from $644 million provided in 2024.
• The company lost its Virginia Medicaid contract, which terminated effective June 30, 2025, after withdrawing a legal protest.
• A temporary reduction in the minimum Interest Coverage Ratio threshold for the New Credit Agreement was executed on February 4, 2026, indicating potential financial covenant pressure.
• A putative securities class action and a shareholder derivative suit were filed in late 2025, alleging violations of federal securities laws and breach of fiduciary duty.

Risks

• Medicaid, Medicare, or Marketplace capitation rates may be insufficient to fully cover medical care costs, utilization rates, and member health acuity.
• Federal or state legislative or regulatory changes, including those from the One Big Beautiful Bill Act (OBBBA) or Executive Orders, could reduce Medicaid funding, change federal matching percentages, implement work requirements, block grants, or per capita caps, or impact Marketplace subsidies.
• Budget pressures on state governments and efforts to reduce rates and limit rate increases could adversely affect profitability.
• Evolving Marketplace dynamics, including issues impacting enrollment, special enrollment periods, member choice, premium subsidies, broker rates, risk adjustment estimates, and plan insolvencies, could lead to volatility.
• The inability to retain existing or awarded government contracts, or successfully bid on new ones, could materially reduce premium revenues.
• Inability to successfully integrate acquisitions and realize expected benefits or limit liabilities as projected.
• Subsequent adjustments to reported premium revenue, including retroactive Medicaid rate adjustments or changes to estimated Marketplace risk adjustment amounts.
• Ineffective management of medical costs and inaccurate estimation of incurred but not reported (IBNR) medical costs.
• Cyber-attacks, ransomware attacks, or other privacy or data security incidents involving the company or its contracted vendors could result in operational impact, increased costs, and legal liability.
• Operational improvements, efficiencies, and cost savings from investments in artificial intelligence (AI) administrative tools and initiatives may be less than anticipated or result in unforeseen consequences.
• Inadequate rates to support increasing pharmacy costs, including specialty drugs and formulary changes.
• Uncertainty in the interpretation, implementation, and estimates of amounts owed for federal or state medical cost expenditure floors, administrative cost and profit ceilings, premium stabilization programs, profit-sharing arrangements, and risk adjustment provisions.
• Fraud, waste, and abuse matters, government audits, reviews, or investigations, and any resulting fines, sanctions, or premium recovery.
• The inability to deliver quality care, maintain good relations with providers, or enter into cost-effective contracts with providers could adversely affect profitability.
• Inaccuracies in eligibility lists provided by state governments could negatively affect results of operations.
• The insolvency of a delegated provider could obligate the company to pay its referral claims.
• If a state fails to renew its federal Medicaid waiver application for mandated Medicaid enrollment, membership in that state will likely decrease.
• The company's business depends on its information and medical management systems, and inability to effectively integrate, manage, update, and keep them secure could disrupt operations.
• Inaccurate or incomplete encounter data could adversely affect premium rates, membership assignment, and subject the company to financial penalties.
• An impairment charge with respect to recorded goodwill or finite-lived intangible assets could have a material impact on financial results.
• The value of investments is influenced by varying economic and market conditions, and a decrease in value may result in a loss charged to income.
• Medicaid enrollees continue to be subject to eligibility redeterminations and potential disenrollments, and the number and health acuity level of retained members may be lower than current estimates.
• The termination of the Medicare-Medicaid Plans (MMP) program and transition to integrated D-SNP contracts could impact premium revenues.
• Failure to maintain Medicare Star Ratings above 3.0 or improve them could negatively impact revenues and benefits offered.
• Government audits, including CMS RADV audits, could result in significant adjustments in payments.
• If state regulators do not approve payments of dividends and distributions by subsidiaries, it may negatively affect the parent company's ability to meet debt service and other obligations.
• The company is subject to extensive fraud and abuse laws that may give rise to lawsuits and claims, including False Claims Act and Qui tam actions.
• Noncompliance with privacy, security, or data protection laws and regulations, or any security breach, could result in significant liability and negative publicity.
• Unforeseen changes in pharmaceutical regulations or market conditions may impact revenues and adversely affect results of operations due to high-cost specialty drugs and cost inflation.
• Large-scale medical emergencies in one or more states could significantly increase utilization rates and medical costs.
• Changes to laws and regulations governing the business, or their interpretation and enforcement, could require operational modifications and negatively impact operating results.
• Adverse credit market conditions may have a material adverse effect on liquidity or ability to obtain credit on acceptable terms.
• Restrictive covenants in debt instruments may restrict the ability to pursue business strategies or have other adverse consequences.
• The success of the business is highly dependent on the leadership of its chief executive officer and other executive officers and key employees, and the loss of their leadership could negatively impact operations.
• Risks related to litigation or arbitration, including provider claims, employment claims, class actions, and derivative actions, could result in substantial costs and negative media attention.
• Failure to maintain effective internal controls over financial reporting could have a material adverse effect on business, operating results, and stock price.
• Business operations may be disrupted as a result of a major earthquake or wildfire in Southern California, where corporate headquarters are located.
• Changes in tax laws or regulations that are applied adversely to the company or its customers may materially adversely affect business, prospects, financial condition, and operating results.

Future Outlook

Molina Healthcare expects Medicaid enrollment to be flat in 2026, with modest contraction offset by new contract implementations. Medicare enrollment is projected to decrease by approximately 12% in 2026 to 230,000 members due to strategic positioning, and the company intends to exit its MAPD product for 2027, anticipating a $93 million impairment charge. Marketplace enrollment is expected to decrease to 220,000 members by the end of 2026, aiming to restore target margins. The company maintains long-term premium revenue and net income growth targets of 11% to 13%, expecting to surpass $50 billion in premium revenue by 2027. The One Big Beautiful Bill Act (OBBBA) is projected to reduce Medicaid Expansion membership by 15% to 20% by 2029, with changes to provider taxes and payment limits starting in 2028. Future refinancing may occur at higher interest rates, increasing the cost of capital, and dividends from subsidiaries are expected to decline in 2026.

Management Comments

• "We are pleased with the continued success of our profitable growth strategy in 2025, which included strong performance on Medicaid state procurements in 2025, and the ConnectiCare acquisition that we closed as of February 1, 2025."
• "We have confidence that we can continue to execute our strategic plan, despite the significant environmental challenges presented in the near term of rapidly escalating medical care costs and utilization."
• "Our proven record of RFP success makes us confident in our ability to retain current revenue and to pursue most new state opportunities with a continued high win rate."
• "We remain opportunistic about deploying capital to accretive acquisitions."
• "The current challenging operating environment has been a catalyst for many smaller and less diverse health plans to consider their strategic options."
• "We are promoting strong medical and general and administrative (G&A) cost management to drive attractive and sustainable margins."
• "We are advancing capabilities to drive medical cost efficiencies with a focus on high-acuity populations, including care management, value-based contracting, payment integrity, and centers of excellence for behavioral health, pharmacy, and Long-Term Services and Supports (LTSS)."
• "As part of our operating enhancements, we are making appreciable investments in deploying artificial intelligence (AI) tools to enhance effectiveness and create efficiency."
• "We are focused on continuing to maintain a strong capital foundation and retaining enough flexibility to execute on all three pillars of our capital allocation strategy."
• "We determined that the MAPD product does not align with our strategic shift to focus exclusively on dual eligible members in Medicare and we intend to exit this product for 2027."
• "Management believes that our regulated, wholly owned subsidiaries remain well capitalized and exceed their regulatory minimum requirements."

Industry Context

StockSavvy.ai notes that Molina Healthcare's challenges with rising medical costs and utilization, particularly in Medicaid and Medicare, reflect broader industry trends impacting managed care organizations. The legislative changes introduced by the One Big Beautiful Bill Act (OBBBA) and the Marketplace Program Integrity and Affordability Rule highlight increasing governmental scrutiny and potential for reduced enrollment and funding across government-sponsored healthcare programs. The company's strategic shift towards dual-eligible Medicare members and away from general MAPD products, alongside significant investments in AI for operational efficiency, aligns with an industry-wide focus on optimizing high-acuity care management and leveraging technology to combat cost pressures. The consolidation trend, as evidenced by Molina's acquisitions and its observation that smaller plans are considering strategic options, indicates a competitive environment where scale and efficiency are increasingly critical.

Comparison to Industry Standards

• Molina's consolidated MCR of 91.7% in 2025 is above its long-term target range, indicating higher medical costs relative to premiums compared to its own historical performance and potentially industry benchmarks.
• The G&A ratio of 6.6% in 2025, a decrease from 6.7% in 2024, suggests strong operating discipline, potentially outperforming some competitors in administrative efficiency given the revenue growth.
• Molina's 90% re-procurement win rate for Medicaid RFPs and 80% new contract win rate are strong indicators of competitive success in government contracting, potentially exceeding the average for large national health plans like Centene Corporation, CVS Health Corporation, Elevance Health, Inc., and UnitedHealth Group Inc.
• The decline in net income and pre-tax margin suggests underperformance relative to its own prior year and potentially some industry peers who may have managed cost trends more effectively or benefited from different market mixes.
• The increase in Medicare Star Ratings for 2026, with two additional plans reaching 3.5 Stars and one reaching 4.5 Stars, positions Molina competitively against peers like Humana, Inc. and UnitedHealth Group Inc., as higher ratings lead to enhanced benefits and quality-bonus payments.

Corporate Governance

Legal Proceedings

• On October 3, 2025, a putative securities class action, 'Hindlemann v. Molina Healthcare, Inc., et al.', was filed in the United States District Court for the Central District of California against the Company, its Chief Executive Officer, and Chief Financial Officer. The suit alleges violations of federal securities laws related to the Company's disclosures, including earnings guidance, between February 5, 2025, and July 23, 2025.
• On December 12, 2025, a shareholder derivative suit, 'Taylor v. Wolf, et al.', was filed in the United States District Court for the Central District of California against the Company's directors and certain officers. This suit asserts claims for breach of fiduciary duty and violation of securities laws in connection with the same statements and events at issue in the Securities Action.
• The Company intends to vigorously contest both lawsuits and cannot predict the outcome or provide a reasonable estimate of the possible loss at this time.

Stakeholder Impact

• Shareholders: Experienced a significant decrease in net income and diluted EPS, but benefited from substantial stock repurchase programs. Face uncertainty from rising costs, legislative changes, and ongoing litigation.
• Employees: Benefit from competitive total rewards, including comprehensive health insurance, 401(k) matching, paid parental leave, volunteer time off, wellness programs, and an Employee Stock Purchase Plan. The company focuses on attracting and retaining top talent and fostering engagement.
• Customers (State and Federal Governments): Benefit from Molina's commitment to providing low-cost, high-quality health plans and reliable service. Impacted by legislative changes like the OBBBA, which could alter program structures and funding.
• Members: Benefit from access to high-quality, affordable care, including preventive services and care management. Affected by Medicaid eligibility redeterminations, Marketplace subsidy changes, and strategic shifts like the exit from MAPD products.
• Providers: Form a vast network essential for member care. Relationships are based on reimbursement rates, claims payment timeliness, and administrative capabilities. Potential for disputes over out-of-network compensation under laws like the No Surprises Act.
• Creditors: Impacted by the company's debt structure, including new senior notes and a refinanced credit facility. The temporary reduction in the Interest Coverage Ratio threshold indicates potential monitoring of financial health.

Next Steps

• Implement new Medicaid and Medicare contracts in Idaho, Michigan, Massachusetts, Ohio, Wisconsin, Nevada, and Illinois, which commenced on January 1, 2026.
• Transition Medicare-Medicaid Plans (MMP) to integrated Dual Eligible Special Needs Plans (D-SNP) in Illinois, Michigan, Ohio, South Carolina, and Texas, effective January 1, 2026.
• Address the accounting impacts of the planned exit from the MAPD product for 2027 in the first quarter of 2026, including an estimated pre-tax impairment charge of approximately $93 million.
• Commence the new Florida Kids contract, expected to begin in the fourth quarter of 2026.
• Continue to execute the $1 billion common stock repurchase program, with $500 million remaining available through December 31, 2026.
• Pursue targeted accretive acquisitions to support continued growth.
• Promote strong medical and general and administrative (G&A) cost management to drive attractive and sustainable margins.
• Advance capabilities to drive medical cost efficiencies, with a focus on high-acuity populations, including care management, value-based contracting, payment integrity, and centers of excellence.
• Continue appreciable investments in deploying artificial intelligence (AI) tools to enhance effectiveness and create efficiency.
• Monitor and adapt to the implementation of the One Big Beautiful Bill Act (OBBBA) changes, including Medicaid work requirements, redeterminations, and cost-sharing, which are phased in from 2027 to 2029.
• Monitor and adapt to the Marketplace Program Integrity and Affordability Rule, which shortens the Open Enrollment Period (OEP) starting in 2027 and tightens eligibility verification.
• Vigorously contest the putative securities class action and shareholder derivative suit filed in late 2025.
• Monitor and evaluate the impact of new accounting standards, including ASU 2024-03 (effective 2027) and ASU 2025-06 (effective 2028).

Key Dates

Recommendation

Molina Healthcare is navigating a complex environment with significant headwinds from rising medical costs and legislative changes impacting government-sponsored programs, leading to a substantial decline in net income and pre-tax margins in 2025. While the company demonstrates strong strategic execution in securing new contracts and maintaining operational efficiency (G&A ratio improvement), the immediate financial performance is concerning. The strategic shift to focus on dual-eligible Medicare members and exit MAPD, coupled with investments in AI, shows proactive adaptation. However, the uncertainty surrounding the impact of the OBBBA, ongoing litigation, and the need to restore target margins suggest a period of adjustment. A "hold" recommendation is appropriate as investors await clearer signs of margin stabilization and the successful realization of benefits from strategic repositioning and cost management initiatives.

Keywords

Healthcare, Managed Care, Medicaid, Medicare, Marketplace, Health Insurance, 10-K, Financial Results, Medical Care Ratio, MCR, Revenue, Net Income, Acquisitions, ConnectiCare, Government Contracts, Risk Adjustment, Cybersecurity, AI, Stock Repurchase, Debt, Capital Management, Regulatory Compliance, Provider Networks, OBBBA, One Big Beautiful Bill Act, APTC, Premium Subsidies, Star Ratings, Internal Controls